NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in NDMM
A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM